Promoter methylation of the bone morphogenetic protein-6 gene in association with adult T-cell leukemia
Ayuko Taniguchi
Department of Hematology and Respiratory Medicine, Kochi Medical School, Kochi University, Kochi, Japan
Search for more papers by this authorYuiko Nemoto
Department of Hematology and Respiratory Medicine, Kochi Medical School, Kochi University, Kochi, Japan
Search for more papers by this authorAkihito Yokoyama
Department of Hematology and Respiratory Medicine, Kochi Medical School, Kochi University, Kochi, Japan
Search for more papers by this authorNorihiro Kotani
Department of Biochemistry, Kochi Medical School, Kochi University, Kochi, Japan
Search for more papers by this authorShosuke Imai
Department of Molecular Microbiology and Infections, Kochi Medical School, Kochi University, Kochi, Japan
Search for more papers by this authorTaro Shuin
Department of Urology, Kochi Medical School, Kochi University, Kochi, Japan
Search for more papers by this authorCorresponding Author
Masanori Daibata
Department of Hematology and Respiratory Medicine, Kochi Medical School, Kochi University, Kochi, Japan
Fax: +81-88-880-2348.
Department of Hematology and Respiratory Medicine, Kochi Medical School, Kochi University, Kochi 783-8505, JapanSearch for more papers by this authorAyuko Taniguchi
Department of Hematology and Respiratory Medicine, Kochi Medical School, Kochi University, Kochi, Japan
Search for more papers by this authorYuiko Nemoto
Department of Hematology and Respiratory Medicine, Kochi Medical School, Kochi University, Kochi, Japan
Search for more papers by this authorAkihito Yokoyama
Department of Hematology and Respiratory Medicine, Kochi Medical School, Kochi University, Kochi, Japan
Search for more papers by this authorNorihiro Kotani
Department of Biochemistry, Kochi Medical School, Kochi University, Kochi, Japan
Search for more papers by this authorShosuke Imai
Department of Molecular Microbiology and Infections, Kochi Medical School, Kochi University, Kochi, Japan
Search for more papers by this authorTaro Shuin
Department of Urology, Kochi Medical School, Kochi University, Kochi, Japan
Search for more papers by this authorCorresponding Author
Masanori Daibata
Department of Hematology and Respiratory Medicine, Kochi Medical School, Kochi University, Kochi, Japan
Fax: +81-88-880-2348.
Department of Hematology and Respiratory Medicine, Kochi Medical School, Kochi University, Kochi 783-8505, JapanSearch for more papers by this authorAbstract
Bone morphogenetic proteins (BMP), belonging to the transforming growth factor-β superfamily, are multifunctional regulators of cell proliferation, differentiation and apoptosis in various types of malignant cells. In this study, we investigated BMP-6 promoter methylation in patients with various types of leukemias. The BMP-6 methylation was found preferentially in adult T-cell leukemia (ATL) (49 of 60, 82%) compared with other types of leukemias studied including acute myeloid leukemia (3 of 67, 5%), acute lymphoblastic leukemia (6 of 38, 16%) and chronic lymphocytic leukemia (1 of 21, 5%). Among subtypes of ATL, the BMP-6 gene was more frequently methylated in aggressive ATL forms of acute (96%) and lymphoma (94%) types than less malignant chronic ATL (44%) and smoldering ATL (20%). We also analyzed the methylation status of peripheral blood mononuclear cells from healthy donors and nonmalignant lymph nodes with reactive lymphadenopathy, none of which showed detectable BMP-6 methylation in this study. The BMP-6 methyaltion was correlated with decreased mRNA transcript and protein expression. Expression of BMP-6 was restored by the demethylating agent 5-aza-2′-deoxycytidine, suggesting that methylation was associated with the transcriptional silencing. Serial analysis demonstrated an increasing methylation of CpG sites in the BMP-6 promoter and the resultant suppression of BMP-6 expression as ATL progressed. These findings suggested that BMP-6 promoter methylation is likely to be a common epigenetic event at later stages of ATL and that the methylation profiles may be useful for the staging of ATL as well as for evaluation of the individual risk of developing the disease. © 2008 Wiley-Liss, Inc.
References
- 1 Uchiyama T,Yodoi J,Sagawa K,Takatsuki K,Uchino H. Adult T-cell leukemia: clinical and hematologic features of 16 cases. Blood 1977; 50: 481–92.
- 2 Yoshida M,Miyoshi I,Hinuma Y. Isolation and characterization of retrovirus from cell lines of human adult-cell leukemia and its implication in the disease. Proc Natl Acad Sci USA 1982; 79: 2031–5.
- 3 Shimoyama M. Diagnostic criteria and classification of clinical subtypes of adult T-cell leukaemia-lymphoma: a report from the Lymphoma Study Group (1984–1987). Br J Haematol 1991; 79: 428–37.
- 4 Yoshida M. Multiple viral strategies of HTLV-1 for dysregulation of cell growth control. Annu Rev Immunol 2001; 19: 475–96.
- 5 Sakashita A,Hattori T,Miller CW,Suzushima H,Asou N,Takatsuki K,Koeffler HP. Mutation of the p53 gene in adult T-cell leukemia. Blood 1992; 79: 477–80.
- 6 Cesarman E,Chadburn A,Inghirami G,Gaidano G,Knowles DM. Structural and functional analysis of oncogene and tumor suppressor genes in adult T-cell leukemia/lymphoma shows frequent p53 mutations. Blood 1992; 80: 3205–16.
- 7 Nishimura S,Asou N,Suzushima H,Okubo T,Fujimoto T,Osato M,Yamasaki H,Lisha L,Takatsuki K. p53 gene mutation and loss of heterozygosity are associated with increased risk of disease progression in adult T-cell leukemia. Leukemia 1995; 9: 598–604.
- 8 Tamiya S,Etoh K,Suzushima H,Takatsuki K,Matsuoka M. Mutation of CD95 (Fas/Apo-1) gene in adult T-cell leukemia cells. Blood 1998; 91: 3935–42.
- 9 Maeda T,Yamada Y,Moriuchi R,Sugahara K,Tsuruda K,Joh T,Atogami S,Tsukasaki K,Tomonaga M,Kamihira S. Fas gene mutation in the progression of adult T-cell leukemia. J Exp Med 1999; 189: 1063–71.
- 10 Hatta Y,Hirama T,Miller CW,Yamada Y,Tomonaga M,Koeffler HP. Homozygous deletions of the p15 (MTS2) and p16 (CDKN2/MTS1) genes in adult T-cell leukemia. Blood 1995; 85: 2699–704.
- 11 Uchida T,Kinoshita T,Watanabe T,Nagai H,Murate T,Saito H,Hotta T. The CDKN 2 gene alterations in various types of adult T-cell leukaemia. Br J Haematol 1996; 94: 665–70.
- 12 Morosetti R,Kawamata N,Gombart AF,Miller CW,Hatta Y,Hirama T,Said JW,Tomonaga M,Koeffler HP. Alterations of the p27KIP1 gene in non-Hodgkin's lymphomas and adult T-cell leukemia/lymphoma. Blood 1995; 86: 1924–30.
- 13 Nosaka K,Maeda M,Tamiya S,Sakai T,Mitsuya H,Matsuoka M. Increasing methylation of the CDKN2A gene is associated with the progression of adult T-cell leukemia. Cancer Res 2000; 60: 1043–8.
- 14 Yasunaga J,Taniguchi Y,Nosaka K,Yoshida M,Satou Y,Sakai T,Mitsuya H,Matsuoka M. Identification of aberrantly methylated genes in association with adult T-cell leukemia. Cancer Res 2004; 64: 6002–9.
- 15 De Caestecker MP,Piek E,Robert AB. Role of transforming growth factor-β signaling in cancer. J Natl Cancer Inst 2000; 92: 1388–1402.
- 16 Massague J,Blain SW,Lo RS. TGF-β signaling in growth control, cancer, and heritable disorders. Cell 2000; 103: 295–309.
- 17 Derynck R,Akhurst RJ,Balmain A. TGF-β signaling in tumor suppression and cancer progression. Nat Genet 2001; 29: 117–29.
- 18 Siegel PM,Massague J. Cytostatic and apoptotic actions of TGF-β in homeostasis and cancer. Nat Rev Cancer 2003; 3: 807–21.
- 19 Bierie B,Moses HL. TGF-β and cancer. Cytokine Growth Factor Rev 2006; 17: 29–40.
- 20 Massague J. TGF-β sginal transduction. Annu Rev Biochem 1998; 67: 753–91.
- 21 Miyazono K,Maeda S,Imamura T. BMP receptor signaling: transcriptional targets, regulation of signals, and signaling cross-talk. Cytokine Growth Factor Rev 2005; 16: 251–63.
- 22 Bhatia M,Bonnet D,Wu D,Murdoch B,Wrana J,Gallacher L,Dick JE. Bone morphogenetic proteins regulate the developmental program of human hematopoietic stem cells. J Exp Med 1999; 189: 1139–47.
- 23 Kawabata M,Imamura T,Miyazono K. Signal transduction by bone morphogenetic proteins. Cytokine Growth Factor Rev 1998; 9: 49–61.
- 24 Horvath LG,Henshall SM,Kench JG,Turner JJ,Golovsky D,Brenner PC,O'Neill GF,Kooner R,Stricker PD,Grygiel JJ,Sutherland RL. Loss of BMP2, Smad8, and Smad4 expression in prostate cancer progression. Prostate 2004; 59: 234–42.
- 25 Harwick JCH,van den Brink GR,Bleuming SA,Ballester I,van den Brande JMH,Keller JJ,Offerhaus GJA,van Deventer SJH,Peppelenbosch MP. Bone morphogenetic protein 2 is expressed by, and acts upon, mature epithelial cells in the colon. Gastroenterol 2004; 126: 111–21.
- 26 Wen XZ,Akiyama Y,Baylin SB,Yuasa Y. Frequent epigenetic silencing of the bone morphogenetic protein 2 gene through methylation in gastric carcinomas. Oncogene 2006; 25: 2666–73.
- 27 Dai Z,Lakshmanan RR,Zhu WG,Smiraglia D,Rush LJ,Frühwald MC,Brena RM,Li B,Wright FA,Ross P,Otterson GA,Plass C. Global methyaltion profiling of lung cancer identifies novel methylated genes. Neoplasia 2001; 3: 314–23.
- 28 Dai Z,Popkie AP,Zhu WG,Timmers CD,Raval A,Tannehill-Gregg S,Morrison CD,Auer H,Kratzke RA,Niehans G,Amatschek S,Sommergruber W, et al. Bone morphogenetic protein 3B silencing in non-small-cell lung cancer. Oncogene 2004; 23: 3521–9.
- 29 Kraunz KS,Nelson HH,Liu M,Wiencke JK,Kelsey KT. Interaction between the bone morphogenetic proteins and Ras/MAP-kinase signaling pathways in lung cancer. Br J Cancer 2005; 93: 949–52.
- 30 Loh K,Chia A,Greco S,Cozzi SJ,Buttenshaw RL,Bond CE,Simms LA,Pike T,Young JP,Jass JR,Spring KJ,Leggett BA, et al. Bone morphogenic protein 3 inactivation is an early and frequent event in colorectal cancer development. Gene Chromosome Cancer 2008; 47: 449–60.
- 31 Tamada H,Kitazawa R,Gohji K,Kamidono S,Maeda S,Kitazawa S. Molecular cloning and analysis of the 5′-flanking region of the human bone morphogenetic protein-6 (BMP-6). Biochim Biophys Acta 1998; 1395: 247–51.
- 32 Daibata M,Nemoto Y,Bandobashi K,Kotani N,Kuroda M,Tsuchiya M,Okuda H,Takakuwa T,Imai S,Shuin T,Taguchi H. Promoter hypermethylation of the bone morphogenetic protein-6 gene in malignant lymphoma. Clin Cancer Res 2007; 13: 3528–35.
- 33 Xiong Z,Laird PW. COBRA: a sensitive and quantitative DNA methylation assay. Nucleic Acids Res 1997; 25: 2532–4.
- 34 Daibata M,Taguchi T,Nemoto Y,Saito T,Machida H,Imai S,Miyoshi I,Taguchi H. Epstein-Barr virus (EBV)-positive pyothorax-associated lymphoma (PAL): chromosomal integration of EBV in a novel CD2-positive PAL B-cell line. Br J Haematol 2002; 117: 546–57.
- 35 Hamdy FC,Autzen P,Robinson MC,Horne CHW,Neal DE,Robson CN. Immunolocalization and messenger RNA expression of bone morphogenetic protein-6 in human benign and malignant prostatic tissue. Caner Res 1997; 57: 4427–31.
- 36 Hinuma Y,Nagata K,Hanaoka M,Nakai M,Matsumoto T,Kinoshita K,Shirakawa S,Miyoshi I. Adult T-cell leukemia: antigen in an ATL cell line and detection of antibodies to the antigen in human sera. Proc Natl Acad Sci USA 1981; 78: 6476–80.
- 37 Hoshino H,Esumi H,Miwa M,Shimoyama M,Minato K,Tobinai K,Hirose M,Watanabe S,Inada N,Kinoshita K,Kamihira S,Ichimaru M, et al. Establishment and characterization of 10 cell lines derived from patients with adult T-cell leukemia. Proc Natl Acad Sci USA 1983; 80: 6061–5.
- 38 Levy L,Hill CS. Alterations in components of the TGF-β superfamily signaling pathways in human cancer. Cytokine Growth Factor Rev 2006; 17: 41–58.
- 39 Varga AC,Wrana JL. The disparate role of BMP in stem cell biology. Oncogene 2005; 24: 5713–21.
- 40 Haudenschild DR,Palmer SM,Moseley TA,You Z,Reddi AH. Bone morphogenetic protein (BMP)-6 signaling and BMP antagonist noggin in prostate cancer. Cancer Res 2004; 64: 8276–84.
- 41 Wach S,Schirmacher P,Protschka M,Blessing M. Overexpression of bone morphogenetic protein-6 (BMP-6) in murine epidermis suppresses skin tumor formation by induction of apoptosis and downregulation of fos/jun family members. Oncogene 2001; 20: 7761–9.
- 42 Kim IY,Lee DH,Lee DK,Kim BC,Kim HT,Leach FS,Linehan WM,Morton RA,Kim SJ. Decreased expression of bone morphogenetic protein (BMP) receptor type II correlates with insensitibity to BMP-6 in human renal cell carcinoma cells. Clin Cancer Res 2003; 9: 6046–51.
- 43 Kraunz KS,Nelson HH,Liu M,Wiencke JK,Kelsey KT. Interaction between the bone morphogenetic proteins and Ras/MAP-kinase signaling pathways in lung cancer. Br J Cancer 2005; 93: 949–52.
- 44 Zhang M,Wang Q,Yuan W,Yang S,Wang X,Yan JD,Du J,Yin J,Gao SY,Sun BC,Zhu TH. Epigenetic regulation of bone morphogenetic protein-6 gene expression in breast cancer cells. J Steroid Biochem Mol Biol 2007; 105: 91–7.
- 45 Ro TB,Holt RU,Brenne AT,Hjorth-Hansen H,Waage A,Hjertner O,Sundan A,Borset M. Bone morphogenetic protein-5, -6 and -7 inhibit growth and induce apoptosis in human myeloma cells. Oncogene 2004; 23: 3024–32.
- 46 Fortunel NO,Halzfeld A,Halzfeld JA. Transform growth factor-β: pleiotropic role in the regulation of hematopoiesis. Blood 2000; 96: 2022–36.
- 47 Wolfraim LA,Fernandez TM,Mamura M,Fuller WL,Kumar R,Cole DE,Byfield S,Felici A,Flanders KC,Walz TM,Roberts AB,Aplan PD, et al. Loss of Smad3 in acute T-cell lymphoblastic leukemia. N Engl J Med 2004; 351: 552–9.
- 48 Lin HK,Bergmann S,Pandolfi PP. Deregulated TGF-β signaling in leukomogenesis. Oncogene 2005; 24: 5693–700.
- 49 Mori N,Morishita M,Tsukazaki T,Giam CZ,Kumatori A,Tanaka Y,Yamamoto N. Human T-cell leukemia virus type I oncoprotein Tax represses Smad-dependent transform growth factor b signaling through interaction with CREB-binding protein/p300. Blood 2001; 97: 2173–44.
- 50 Lee DK,Kim BC,Brady JN,Jeang KT,Kim SJ. Human T-cell lymphotropic virus type I tax inhibits transform growth factor-β signaling by blocking the association of smad protein with smad-binding element. J Biol Chem 2002; 37: 33766–75.
- 51 Amulf B,Villemain A,Nicot C,Mordelet E,Chameau P,Kersual J,Zermati Y,Mauviel A,Bazarbachi A,Hermine O. Human T-cell lymphotropic virus oncoprotein Tax represses TGF-β signaling in human T cells via c-Jun activation: a potential mechanism of HTLV-I leukomogenesis. Blood 2002; 100: 4129–38.
- 52 Derynck R,Goeddel DV,Ullrich A,Gutterman JU,Williams RD,Bringman TS,Berger WH. Synthesis of messenger RNAs for transforming growth factor α and β and the epidermal growth factor receptor by human tumors. Cancer Res 1987; 47: 707–12.
Citing Literature
